Cmaj Podcasts

New prescriptions for stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD) doubled during the COVID-19 pandemic compared with the years before it, with the largest increases among adults aged 18 to 34 and among women.Dr. Tara Gomes, a professor at the University of Toronto and principal investigator of the Ontario Drug Policy Research Network, discusses findings from the CMAJ research article Patterns of prescription stimulant initiation before and during the COVID-19 pandemic. Her team found that the number of Ontarian adults newly starting stimulants rose rapidly after an initial drop early in the pandemic. The interval between a first ADHD-related health care encounter and a stimulant prescription also fell from about seven years before the pandemic to less than one year during it. Gomes suggests the increase likely reflects both improved recognition of ADHD in adults and easier access through virtual care, which may be shortening the pathway from first expression of concern